Altraz Tablet is a specialized pharmaceutical formulation containing 1 mg of Anastrozole, a potent aromatase inhibitor developed and manufactured by Cipla Ltd. Specifically designed for the effective management of hormone receptor-positive breast cancer in postmenopausal women, this oral tablet operates by selectively inhibiting the aromatase enzyme, thus reducing estrogen production that fuels cancer growth. Altraz is indicated as an adjuvant treatment to prevent recurrence, as first-line or post-tamoxifen metastatic therapy, and as extended adjuvant therapy to mitigate cancer recurrence risks. With a convenient once-daily dosage and a well-tolerated safety profile compared to older hormonal therapies, Altraz Tablet supports long-term patient compliance and efficacy. It is supplied in blister packs or bottles containing 14 or 28 tablets each for optimized inventory management and ease of distribution. The product must be stored under controlled conditions below 30°C, protected from light and moisture to maintain its stability. Strict medical supervision is essential, including regular monitoring of bone mineral density due to osteoporosis risks associated with estrogen suppression. Altraz Tablet stands out as a trusted oncological hormonal therapy facilitating targeted and effective breast cancer management in postmenopausal women.
Key Features
| Features | Description |
|---|---|
| Active Ingredient | Anastrozole 1 mg |
| Therapeutic Category | Oncology / Hormonal Therapy (Aromatase Inhibitor) |
| Indications | Hormone receptor-positive breast cancer in postmenopausal women (adjuvant, metastatic, extended adjuvant therapy) |
| Mechanism of Action | Selective inhibition of aromatase enzyme to reduce estrogen levels |
| Dosage | 1 mg tablet once daily, with or without food |
| Duration of Treatment | Typically 5 years or as prescribed by oncologist |
| Packaging | Blister pack or bottle of 14 or 28 tablets |
| Storage Conditions | Store below 30°C, in a dry place, protected from light and moisture |
| Patient Population | Postmenopausal women only |
| Warnings | Not for premenopausal women, pregnancy, or breastfeeding; monitor bone density regularly |
| Manufacturer | Cipla Ltd. |
| Attributes | Description |
|---|---|
| Generic Name | Anastrozole |
| Brand Name | Altraz |
| Strength | 1 mg per tablet |
| Formulation | Oral tablet |
| Therapeutic Use | Hormonal therapy for breast cancer |
| Treatment Type | Oncology - Aromatase inhibitor |
| Regimen | Once daily |
| Packaging Types | Blister pack and bottles |
| Shelf Life | As per manufacturer labeling |
| Storage Requirements | Below 30°C, away from moisture and light |
| Manufacturer Details | Cipla Ltd., India |
*Disclaimer: The above description has been AI-generated and has not been audited or verified for accuracy. It is recommended to verify product details independently before making any purchasing decisions.
No, Altraz Tablet containing Anastrozole is not recommended for premenopausal women due to insufficient efficacy and safety profile in this patient group.
Altraz Tablets should be stored below 30°C in a dry place, protected from light and moisture to ensure stability and potency.
Yes, Altraz Tablet is indicated for extended adjuvant therapy to reduce the risk of breast cancer recurrence post initial treatment.
Regular monitoring of bone mineral density is essential during treatment with Altraz Tablet as it can increase osteoporosis risk; also, usage is contraindicated in pregnant or breastfeeding women.
Altraz Tablet can be used as a first-line or second-line (after tamoxifen failure) treatment in metastatic hormone receptor-positive breast cancer, offering a different mechanism by selective aromatase inhibition.
Country Of Origin: India
Product Name: Altraz Tablet
Generic Name: Anastrozole 1 mg
Manufacturer: Cipla Ltd. (Brand: Altraz)
Therapeutic Category: Oncology / Hormonal Therapy (Aromatase Inhibitor)
Product Description:
Altraz Tablet contains Anastrozole, a potent aromatase inhibitor used in the treatment of hormone receptor-positive breast cancer in postmenopausal women.
It works by lowering estrogen levels in the body, thereby slowing or stopping the growth of estrogen-dependent tumors.
Indications:
• Hormone receptor-positive breast cancer (adjuvant treatment) in postmenopausal women
• Metastatic breast cancer (first-line or after tamoxifen failure)
• Extended adjuvant therapy to reduce cancer recurrence
Mechanism of Action:
• Anastrozole selectively inhibits the aromatase enzyme, which converts androgens into estrogens.
• Lower estrogen levels reduce stimulation of hormone-dependent breast cancer cells, slowing tumor progression.
Dosage & Administration:
• Usual dose: 1 mg tablet once daily, with or without food.
• Treatment duration: typically 5 years, or as prescribed by an oncologist.
Key Benefits:
• Proven efficacy in reducing breast cancer recurrence.
• Well-tolerated compared to older hormonal therapies.
• Convenient once-daily oral administration.
Packaging:
• Blister pack / Bottle of 14 or 28 tablets (1 mg each).
Storage:
• Store below 30°C, in a dry place.
• Protect from light and moisture.
Important Notes:
• For use in postmenopausal women only.
• Not recommended in premenopausal women, pregnancy, or breastfeeding.
• Regular monitoring of bone mineral density is advised (risk of osteoporosis).
• Use only under strict medical supervision.
Melizza Lifescience
Oncology Exporters from India
Exporters of Pharmaceutical from India
Pharmaceutical products
Cancer vaccines
Inclusive of all taxes
You Save: 0
Rajkot , India
Manufacturer, Professional Services, Distributor, Exporter, Importer, Wholesaler, Startup
GST- 24gqfpm5460r1z4
